Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook

Bladder cancer is the sixth most common cancer in the US and most tumors have urothelial (transitional cell) histology. Platinum-based chemotherapy has long been the standard of care in advanced disease, but long-term outcomes have largely remained poor. Since the peak incidence of bladder cancer is...

Descripción completa

Detalles Bibliográficos
Autores principales: Gopalakrishnan, Dharmesh, Koshkin, Vadim S, Ornstein, Moshe C, Papatsoris, Athanasios, Grivas, Petros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993034/
https://www.ncbi.nlm.nih.gov/pubmed/29892196
http://dx.doi.org/10.2147/TCRM.S158753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993034/
https://www.ncbi.nlm.nih.gov/pubmed/29892196
http://dx.doi.org/10.2147/TCRM.S158753

Ejemplares similares